These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 34353405)

  • 1. Healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among Thai healthcare personnel who receive 2 doses of a coronavirus disease 2019 (COVID-19) vaccine: A call for considering a booster dose.
    Apisarnthanarak A; Nantapisal S; Pienthong T; Apisarnthanarak P; Weber DJ
    Infect Control Hosp Epidemiol; 2022 Nov; 43(11):1740-1742. PubMed ID: 34353405
    [No Abstract]   [Full Text] [Related]  

  • 2. Effectiveness of Messenger RNA Coronavirus Disease 2019 (COVID-19) Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Cohort of Healthcare Personnel.
    Swift MD; Breeher LE; Tande AJ; Tommaso CP; Hainy CM; Chu H; Murad MH; Berbari EF; Virk A
    Clin Infect Dis; 2021 Sep; 73(6):e1376-e1379. PubMed ID: 33900384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
    Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
    Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating COVID-19 Vaccine Effectiveness for Skilled Nursing Facility Healthcare Personnel, California, USA.
    Magro M; Parriott A; Mitsunaga T; Epson E
    Emerg Infect Dis; 2022 Aug; 28(8):1734-1736. PubMed ID: 35732196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2), delta variant, between two fully vaccinated healthcare personnel.
    Smith LL; Milstone AM; Jibowu M; Luo CH; Morris CP; Mostafa HH; Maragakis LL
    Infect Control Hosp Epidemiol; 2022 Dec; 43(12):1983-1985. PubMed ID: 34743764
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery.
    Yang YJ; Murphy EA; Singh S; Sukhu AC; Wolfe I; Adurty S; Eng D; Yee J; Mohammed I; Zhao Z; Riley LE; Prabhu M
    Obstet Gynecol; 2022 Mar; 139(3):373-380. PubMed ID: 34963127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of standard, contact, and droplet precautions with eye protection for the prevention of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission among home healthcare personnel in hospice and home healthcare settings-King and Snohomish counties, Washington, February-October 2020.
    McMichael TM; Duca LM; Lewis J; Riedo FX; Wilde N; McDonald M; Spitters C; Wechkin HA
    Infect Control Hosp Epidemiol; 2023 Mar; 44(3):510-513. PubMed ID: 35264278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine.
    Fonseca MHG; Pinto ACMD; Silva MFS; de Melo ACL; Vasconcelos GS; Dos Santos ER; de Carvalho Araújo FM; de Andrade LOM
    Emerg Infect Dis; 2022 Jun; 28(6):1237-1240. PubMed ID: 35421324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19.
    Kim JY; Kwon JS; Cha HH; Lim SY; Bae S; Kim SH
    Korean J Intern Med; 2022 Nov; 37(6):1234-1240. PubMed ID: 36217813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National Population.
    Butt AA; Talisa VB; Yan P; Shaikh OS; Omer SB; Mayr FB
    Clin Infect Dis; 2022 Aug; 75(1):e579-e584. PubMed ID: 35245940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of healthcare personnel exposures to patients with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) associated with personal protective equipment.
    Shah VP; Breeher LE; Hainy CM; Swift MD
    Infect Control Hosp Epidemiol; 2022 Jun; 43(6):770-774. PubMed ID: 33975656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitigating healthcare staffing shortages: Should healthcare workers with severe acute respiratory coronavirus virus 2 (SARS-CoV-2) household exposures work?
    Blanchard AC; Lamarre V; Lamarche J; Audy N; Quach C
    Infect Control Hosp Epidemiol; 2023 Jul; 44(7):1204-1206. PubMed ID: 36004794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
    Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
    Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial).
    Muadchimkaew M; Siripongboonsitti T; Wongpatcharawarakul S; Boonsankaew C; Tawinprai K; Soonklang K; Mahanonda N
    Int J Infect Dis; 2022 Nov; 124():190-198. PubMed ID: 36180032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
    Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
    JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconsidering the routine use of contact precautions in preventing the transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) in healthcare settings.
    Rodriguez-Nava G; Diekema DJ; Salinas JL
    Infect Control Hosp Epidemiol; 2023 Jun; 44(6):1035-1037. PubMed ID: 37138546
    [No Abstract]   [Full Text] [Related]  

  • 19. Relative Effectiveness of COVID-19 Vaccination in Healthcare Workers: 3-Dose Versus 2-Dose Vaccination.
    Kim SR; Kang HJ; Jeong HR; Jang SY; Lee JE; Kim DE; Lee HR; Cho MH; Noh JY; Cheong HJ; Kim WJ; Song JY
    J Korean Med Sci; 2022 Sep; 37(35):e267. PubMed ID: 36065651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strong SARS-CoV-2 Antibody Response After Booster Dose of BNT162b2 mRNA Vaccines in Uninfected Healthcare Workers.
    Kwon SR; Kim N; Park H; Minn D; Park S; Roh EY; Yoon JH; Shin S
    J Korean Med Sci; 2022 May; 37(19):e135. PubMed ID: 35578582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.